Form 4: Lixte Biotechnology Director Stephen J. Forman Acquires Shares Through Stock Options
SEC Form 4
Director Stephen J. Forman reports acquisition of Lixte Biotechnology Holdings shares through stock options in lieu of quarterly cash compensation.
Summary
- Stephen J. Forman, a director of Lixte Biotechnology Holdings, Inc., filed a Form 4 detailing changes in beneficial ownership.
- On September 30, 2024, Forman acquired 3,858 shares of common stock through stock options with an exercise price of $1.30.
- These options were granted in lieu of quarterly cash compensation under the Board Compensation Plan and vested immediately.
- Forman also holds various other options and warrants to purchase common stock at different exercise prices and expiration dates.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director. There's no indication of significant positive or negative news.
Positives
- The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future prospects.
- The grant of options in lieu of cash compensation can conserve the company's cash reserves.
Management Comments
- The grant was in lieu of the quarterly cash compensation due to the reporting person under the Board Compensation Plan.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholders as it aligns the director's interests with those of the shareholders.
- The decision to grant options instead of cash compensation could be viewed positively by creditors as it preserves the company's cash position.
Key Dates
| Date | Description |
|---|---|
| 12/07/2018 | Date of warrants to purchase common stock |
| 05/22/2019 | Date of options to purchase common stock |
| 01/06/2021 | Date of options to purchase common stock |
| 06/30/2021 | Date of options to purchase common stock |
| 06/30/2022 | Date of options to purchase common stock |
| 10/16/2022 | Date of options to purchase common stock |
| 12/07/2022 | Date of warrants to purchase common stock |
| 05/22/2024 | Date of options to purchase common stock |
| 06/30/2023 | Date of options to purchase common stock |
| 06/30/2024 | Date of options to purchase common stock |
| 09/30/2024 | Director Stephen J. Forman acquired 3,858 shares of common stock through stock options. |
| 10/28/2024 | Date of signature for the Form 4 filing. |
| 01/06/2026 | Expiration date of options to purchase common stock |
| 06/30/2026 | Expiration date of options to purchase common stock |
| 06/30/2027 | Expiration date of options to purchase common stock |
| 06/30/2028 | Expiration date of options to purchase common stock |
| 06/30/2029 | Expiration date of options to purchase common stock |
| 09/30/2029 | Expiration date of options to purchase common stock |
Keywords
Form 4, Beneficial Ownership, Stock Options, Director, LIXT, Lixte Biotechnology, Stephen Forman, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.